Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas

StatusSuspended
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment suspended Sponsor's reason: Data update in progress. Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 3 entries
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: details revised at 4 of 6 entries
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 20, 2025 to Nov 6, 2025
    • Site details revised
    • Eligibility criteria shortened, about 5 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Tcelltech Inc.
4 trials monitored
See all monitored trials
Sarcoma
1,027 trials monitored
See 70 trials at risk
This is a open-Label, dose-escalation study to evaluate the safety, tolerability and antitumor activity of DIT309 in subjects with advanced bone and soft tissue sarcomas.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.
Trial Details
NCT Number NCT07052383
Lead Sponsor Tcelltech Inc.
Collaborators: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions
(from sponsor)		 Osteosarcoma, Soft Tissue Sarcoma
Related terms Osteosarcoma, Sarcoma
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov